Effects of Fatty Acid Supplementation on Substance Dependent Individuals
NCT ID: NCT00312455
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2004-07-31
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress
NCT00014027
Effects of Omegas 3 and 6 on Alcohol Dependence
NCT01211769
Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence
NCT01735279
Fish Oil vs. Placebo on Subjective Effects of Alcohol
NCT03010917
Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)
NCT01515917
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be randomly assigned to receive either 3 grams of n-3 PUFAs or placebo. Treatment will last 3 months, followed by an observation period of 3 months. Study visits will occur monthly and will last approximately one hour. Study visits will include blood tests and a physical exam. Throughout the study, participants will continue to receive standard substance abuse treatment and will complete urine tests at regular intervals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Drug Treatment
Pro-eicosapentaenoic acid (EPA)
450 mg 5x/day
Pro-docosapentaenoic acid (DPA)
100mg 5x/day
2
Placebo treatment
Placebo
5 capsules/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pro-eicosapentaenoic acid (EPA)
450 mg 5x/day
Pro-docosapentaenoic acid (DPA)
100mg 5x/day
Placebo
5 capsules/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Used substances of abuse during the 3 months prior to study entry
* Enrolled in one of the VA New York Harbor Healthcare System Brooklyn campus substance abuse clinics
Exclusion Criteria
* Major physical illness (e.g., cardiovascular, pulmonary, gastrointestinal, renal, neuromuscular, or endocrine disorder)
* Liver function test greater than one standard deviation above upper normal limit
* Allergic to fish
25 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
VA New York Harbor Healthcare System
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laure Buydens-Branchey, MD
Role: PRINCIPAL_INVESTIGATOR
VA New York Harbor Healthcare System
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DPMC
Identifier Type: -
Identifier Source: secondary_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.